Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLSiso2 siRNA
- Development stage
- Preclinical
- Lead developer
- Universidade de São Paulo
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
GLSiso2 siRNA is a small interfering RNA (siRNA) designed to selectively silence the expression of the GLSiso2 isoform, also known as GAC (glutaminase C), of the kidney-type glutaminase (GLS) enzyme. Glutaminase is a critical enzyme in cancer metabolism, facilitating glutaminolysis by converting glutamine to glutamate to support the bioenergetic and biosynthetic needs of rapidly proliferating cells. Research presented at AACR 2019 by the University of Sao Paulo demonstrated that GLSiso2 is significantly upregulated in high-grade astrocytomas and glioblastoma compared to normal brain tissue. Silencing this specific isoform using siRNA in U87MG glioblastoma cells resulted in decreased cell proliferation, increased apoptosis, and enhanced sensitivity to the chemotherapeutic agent temozolomide, suggesting its potential as a targeted therapeutic strategy for malignant gliomas.
- Other names
- GAC siRNAglutaminase isoform 2 siRNA
02
Targets
Glutaminase 2 (GLS2)
Beyond the preview
Go deeper on GLSiso2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLSiso2 siRNA.